Drug Profile
Autoimmune disorders companion diagnostic - Novartis / Protagen
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Protagen AG
- Class Antibody diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for clinical-Phase-Unknown development in Autoimmune-disorders(Diagnosis) in Unknown
- 20 Dec 2016 Clinical trials in Autoimmune disorders (Diagnosis) (unspecified route)
- 20 Dec 2016 Protagen AG and Novartis complete a collaboration agreement to develop a companion diagnostic for Autoimmune disorders